
Sexual & Reproductive Health Drugs Market by Drugs Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030
Description
Sexual & Reproductive Health Drugs Market by Drugs Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030
The Sexual & Reproductive Health Drugs Market size was estimated at USD 31.64 billion in 2023 and expected to reach USD 35.83 billion in 2024, at a CAGR 13.34% to reach USD 76.03 billion by 2030.
Global Sexual & Reproductive Health Drugs Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Sexual & Reproductive Health Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sexual & Reproductive Health Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Sexual & Reproductive Health Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Bristol Laboratories Ltd., Church & Dwight Co., Inc., Diamond Products, Ferring B.V., Janssen Pharmaceutical Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Viramal Limited.
Market Segmentation & Coverage
This research report categorizes the Sexual & Reproductive Health Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drugs Type
Erectile Dysfunction Drugs
Gender Dysphoria Drugs
Hypoactive Sexual Desire Disorder Drugs
Premature Ejaculation Drugs
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Sexual & Reproductive Health Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sexual & Reproductive Health Drugs Market?
3. What are the technology trends and regulatory frameworks in the Sexual & Reproductive Health Drugs Market?
4. What is the market share of the leading vendors in the Sexual & Reproductive Health Drugs Market?
5. Which modes and strategic moves are suitable for entering the Sexual & Reproductive Health Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Sexual & Reproductive Health Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising population of the elder female demanding medicines
- 5.1.1.2. Demand for contraceptives to prevent unintended pregnancies
- 5.1.1.3. High internet penetration and availability of smartphones and laptops
- 5.1.2. Restraints
- 5.1.2.1. High cost of treatment and diagnostics
- 5.1.3. Opportunities
- 5.1.3.1. Increasing efforts into research and development (R&D) of drugs
- 5.1.3.2. Growing awareness among ladies about the use of contraceptives
- 5.1.3.3. Government concerns and initiatives towards women’s health
- 5.1.4. Challenges
- 5.1.4.1. Enormous financial costs associated with the clinical services
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Sexual & Reproductive Health Drugs Market, by Drugs Type
- 6.1. Introduction
- 6.2. Erectile Dysfunction Drugs
- 6.3. Gender Dysphoria Drugs
- 6.4. Hypoactive Sexual Desire Disorder Drugs
- 6.5. Premature Ejaculation Drugs
- 7. Sexual & Reproductive Health Drugs Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacy
- 7.3. Online Pharmacy
- 7.4. Retail Pharmacy
- 8. Americas Sexual & Reproductive Health Drugs Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Sexual & Reproductive Health Drugs Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Sexual & Reproductive Health Drugs Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Bayer AG
- 12.1.2. Bristol Laboratories Ltd.
- 12.1.3. Church & Dwight Co., Inc.
- 12.1.4. Diamond Products
- 12.1.5. Ferring B.V.
- 12.1.6. Janssen Pharmaceutical Inc.
- 12.1.7. Merck & Co., Inc.
- 12.1.8. Novartis AG
- 12.1.9. Pfizer Inc.
- 12.1.10. Reckitt Benckiser Group PLC
- 12.1.11. Teva Pharmaceutical Industries Ltd.
- 12.1.12. Viatris Inc.
- 12.1.13. Viramal Limited
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET DYNAMICS
- FIGURE 7. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
- FIGURE 8. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.